<?xml version="1.0" encoding="UTF-8"?><measure><measureDetails><uuid>40280381-3d61-56a7-013e-62240559256d</uuid><title>Diabetes: Hemoglobin A1c Poor Control</title><shortTitle>Diab_HbA1c_Ctrl</shortTitle><emeasureid>122</emeasureid><guid>f2986519-5a4e-4149-a8f2-af0a1dc7f6bc</guid><version>2</version><status>Complete</status><nqfid extension="0059" root="2.16.840.1.113883.3.560.1"/><period uuid="71223536-1dfb-4045-92fb-92e29bea4738"><startDate uuid="b614d886-d13a-4293-92fe-c478936ed310">00000101</startDate><stopDate uuid="e458bbd8-0c40-449b-b1ee-8528ba5cf4f3">00001231</stopDate></period><steward id="2.16.840.1.113883.3.464">National Committee for Quality Assurance</steward><developers><developer id="2.16.840.1.113883.3.464">National Committee for Quality Assurance</developer></developers><endorsement id="2.16.840.1.113883.3.560">National Quality Forum</endorsement><description>Percentage of patients 18-75 years of age with diabetes who had hemoglobin A1c &gt; 9.0% during the measurement period.</description><copyright>Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA). 

The Measures are copyrighted but can be reproduced and distributed, without modification, for noncommercial purposes (e.g., use by healthcare providers in connection with their practices). Commercial use is defined as the sale, licensing, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial use of the Measures requires a license agreement between the user and NCQA. NCQA is not responsible for any use of the Measures. 

(c) 2008-2013 National Committee for Quality Assurance. All Rights Reserved. 

Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code sets should obtain all necessary licenses from the owners of the code sets.  NCQA disclaims all liability for use or accuracy of any CPT or other codes contained in the specifications.

CPT(R) contained in the Measure specifications is copyright 2004-2012 American Medical Association. LOINC(R) copyright 2004-2012 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2012 International Health Terminology Standards Development Organisation. ICD-10 copyright 2012 World Health Organization. All Rights Reserved.</copyright><disclaimer>These performance Measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED ?AS IS? WITHOUT WARRANTY OF ANY KIND.

Due to technical limitations, registered trademarks are indicated by (R) or [R] and unregistered trademarks are indicated by (TM) or [TM].</disclaimer><scoring id="PROPOR">Proportion</scoring><types><type id="OUTCOME">Outcome</type></types><stratification>None</stratification><riskAdjustment>None</riskAdjustment><aggregation>None</aggregation><rationale>Diabetes mellitus (diabetes) is a group of diseases characterized by high blood glucose levels caused by the body's inability to correctly produce or utilize the hormone insulin. It is recognized as a leading cause of death and disability in the U.S. and is highly underreported as a cause of death. Diabetes may cause life-threatening, life-ending or life-altering complications, including poor circulation, nerve damage or neuropathy in the feet and eventual amputation. Nearly 60-70 percent of diabetics suffer from mild or severe nervous system damage (American Diabetes Association 2009). 

Randomized clinical trials have demonstrated that improved glycemic control, as evidenced by reduced levels of glycohemoglobin, correlates with a reduction in the development of microvascular complications in both Type 1 and Type 2 diabetes (Diabetes Control and Complications Trial Research Group 1993; Ohkubo 1995). In particular, the Diabetes Control and Complications Trial (DCCT) showed that for patients with Type 1 diabetes mellitus, important clinical outcomes such as retinopathy (an important precursor to blindness), nephropathy (which precedes renal failure), and neuropathy (a significant cause of foot ulcers and amputation in patients with diabetes) are directly related to level of glycemic control (Diabetes Control and Complications Trial Research Group 1993). Similar reductions in complications were noted in a smaller study of intensive therapy of patients with Type 2 diabetes by Ohkubo and co-workers, which was conducted in the Japanese population (Ohkubo et al. 1995).</rationale><recommendations>American Geriatrics Society (Brown et al. 2003):
                
For frail older adults, persons with life expectancy of less than 5 years, and others in whom the risks of intensive glycemic control appear to outweigh the benefits, a less stringent target such as 8% is appropriate. (Quality of Evidence: Level III; Strength of Evidence: Grade B)


American Diabetes Association (2009):

Lowering A1C to below or around 7% has been shown to reduce microvascular and neuropathic complications of type 1 and type 2 diabetes. Therefore, for microvascular disease prevention, the A1C goal for non-pregnant adults in general is &lt;7%. (Level of Evidence: A)

In type 1 and type 2 diabetes, randomized controlled trials of intensive versus standard glycemic control have not shown a significant reduction in CVD outcomes during the randomized portion of the trials. Long-term follow-up of the Diabetes Control and Complications Trial (DCCT) and UK Prospective Diabetes Study (UKPDS) cohorts suggests that treatment to A1C targets below or around 7% in the years soon after the diagnosis of diabetes is associated with long-term reduction in risk of macrovascular disease. Until more evidence becomes available, the general goal of &lt;7% appears reasonable for many adults for macrovascular risk reduction. (Level of Evidence: B)

Subgroup analyses of clinical trials such as the DCCT and UKPDS and the microvascular evidence from the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial suggest a small but incremental benefit in microvascular outcomes with A1C values closer to normal. Therefore, for selected individual patients, providers might reasonably suggest even lower A1C goals than the general goal of &lt;7%, if this can be achieved without significant hypoglycemia or other adverse effects of treatment. Such patients might include those with short duration of diabetes, long life expectancy, and no significant CVD. (Level of Evidence: B)

Conversely, less stringent A1C goals than the general goal of &lt;7% may be appropriate for patients with a history of severe hypoglycemia, limited life expectancy, advanced microvascular or macrovascular complications, and extensive comorbid conditions and those with longstanding diabetes in whom the general goal is difficult to attain despite diabetes self-management education, appropriate glucose monitoring, and effective doses of multiple glucose lowering agents including insulin. (Level of Evidence: C)</recommendations><improvementNotations>Lower score indicates better quality</improvementNotations><references><reference>American Diabetes Association. 2009. ?Standards of Medical Care in Diabetes-2009.? Diabetes Care 2009 32 (Suppl 1):S6-S12.</reference><reference>Brown, A.F., C.M. Mangione, D. Saliba, C.A. Sarkisian. California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. 2003. ?Guidelines for Improving the Care of the Older Person with Diabetes Mellitus.? J Am Geriatr Soc 51(5 Suppl Guidelines):S265-80.</reference><reference>The Diabetes Control and Complications Trial Research Group. 1994. ?The effect of intensive treatment of diabetes and progression of long-term complications in insulin-dependent mellitus.? N Engl J Med 329:977-86.</reference><reference>Ohkubo Y., H. Kishikawa, E. Araki, T. Miyata, S. Isami, S. Motoyoshi, Y. Kojima, N. Furuyoshi, M. Shichiri. 1995. ?Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.? Diabetes Res Clin Pract 28(2):103-17.</reference></references><definitions>None</definitions><guidance>Patient is numerator compliant if most recent HbA1c level &gt;9% or is missing a result or if an HbA1c test was not done during the measurement year.

Only patients with a diagnosis of Type 1 or Type 2 diabetes should be included in the denominator of this measure; patients with a diagnosis of secondary diabetes due to another condition should not be included.</guidance><transmissionFormat>TBD</transmissionFormat><initialPatientPopDescription>Patients 18-75 years of age with diabetes with a visit during the measurement period</initialPatientPopDescription><denominatorDescription>Equals Initial Patient Population</denominatorDescription><denominatorExclusionsDescription>Patients with a diagnosis of gestational diabetes during the measurement period</denominatorExclusionsDescription><numeratorDescription>Patients whose most recent HbA1c level (performed during the measurement period) is &gt;9.0%</numeratorDescription><numeratorExclusionsDescription>Not Applicable</numeratorExclusionsDescription><denominatorExceptionsDescription>None</denominatorExceptionsDescription><measurePopulationDescription>Not Applicable</measurePopulationDescription><measureObservationsDescription>Not Applicable</measureObservationsDescription><supplementalData>For every patient evaluated by this measure also identify payer, race, ethnicity and sex.</supplementalData><qualityMeasureSet uuid="16333d9a-64a3-4d1d-91ca-fe9e2ba8a450">None</qualityMeasureSet>
<finalizedDate value="201404231519-0500"/>
</measureDetails><supplementalDataElements><elementRef id="40280381-3d61-56a7-013e-62240570256f" name="ONC Administrative Sex"/><elementRef id="40280381-3d61-56a7-013e-622405702570" name="Race"/><elementRef id="40280381-3d61-56a7-013e-622405702571" name="Ethnicity"/><elementRef id="40280381-3d61-56a7-013e-622405702572" name="Payer"/></supplementalDataElements><measureGrouping><group sequence="1"><clause displayName="Initial Patient Population 2" type="initialPatientPopulation" uuid="090498FF-FC6A-464E-A7F2-DDCA925F8022"><logicalOp displayName="AND" type="and"><relationalOp displayName="Starts Before Or During" type="SBOD"><elementRef displayName="Occurrence A of Diabetes : Diagnosis, Active" id="40280381-3d61-56a7-013e-62240570256e" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-622405702575" type="qdm"/></relationalOp><relationalOp displayName="&gt;= 18 years Starts Before Start Of" operatorType="Greater Than or Equal To" quantity="18" type="SBS" unit="years"><elementRef displayName="birth date : Patient Characteristic Birthdate" id="40280381-3d61-56a7-013e-622405702573" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-622405702575" type="qdm"/></relationalOp><relationalOp displayName="&lt; 75 years Starts Before Start Of" operatorType="Less Than" quantity="75" type="SBS" unit="years"><elementRef displayName="birth date : Patient Characteristic Birthdate" id="40280381-3d61-56a7-013e-622405702573" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-622405702575" type="qdm"/></relationalOp><relationalOp displayName="During" type="DURING"><logicalOp displayName="OR" type="or"><elementRef displayName="Office Visit : Encounter, Performed" id="40280381-3d61-56a7-013e-62240570257c" type="qdm"/><elementRef displayName="Face-to-Face Interaction : Encounter, Performed" id="40280381-3d61-56a7-013e-62240570257d" type="qdm"/><elementRef displayName="Preventive Care Services - Established Office Visit, 18 and Up : Encounter, Performed" id="40280381-3d61-56a7-013e-62240570257e" type="qdm"/><elementRef displayName="Preventive Care Services-Initial Office Visit, 18 and Up : Encounter, Performed" id="40280381-3d61-56a7-013e-62240570257f" type="qdm"/><elementRef displayName="Home Healthcare Services : Encounter, Performed" id="40280381-3d61-56a7-013e-622405702580" type="qdm"/><elementRef displayName="Annual Wellness Visit : Encounter, Performed" id="40280381-3d61-56a7-013e-622405712581" type="qdm"/></logicalOp><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-622405702575" type="qdm"/></relationalOp><functionalOp displayName="NOT" type="NOT" uuid="26cfa17b-da52-4797-a5c6-f848c6c83e3f"><relationalOp displayName="Ends Before Start Of" type="EBS"><elementRef displayName="Occurrence A of Diabetes : Diagnosis, Active" id="40280381-3d61-56a7-013e-62240570256e" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-622405702575" type="qdm"/></relationalOp></functionalOp></logicalOp></clause><clause displayName="Denominator 1" type="denominator" uuid="A8AC3144-9501-40D8-B083-6D7375529197"><logicalOp displayName="AND" type="and"/></clause><clause displayName="Denominator Exclusions 2" type="denominatorExclusions" uuid="25516976-2CDD-4566-AB38-12621A2AB265"><logicalOp displayName="AND" type="and"><relationalOp displayName="Starts Before Or During" type="SBOD"><elementRef displayName="Occurrence A of Gestational Diabetes : Diagnosis, Active" id="40280381-3d61-56a7-013e-622405712582" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-622405702575" type="qdm"/></relationalOp><functionalOp displayName="NOT" type="NOT" uuid="4c6e71cf-1e59-465d-9c04-8117e39cf052"><relationalOp displayName="Ends Before Start Of" type="EBS"><elementRef displayName="Occurrence A of Gestational Diabetes : Diagnosis, Active" id="40280381-3d61-56a7-013e-622405712582" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-622405702575" type="qdm"/></relationalOp></functionalOp></logicalOp></clause><clause displayName="Numerator 1" type="numerator" uuid="6C1DE691-21BE-4062-85F7-14428B0AB763"><logicalOp displayName="AND" type="and"><logicalOp displayName="OR" type="or"><logicalOp displayName="AND" type="and"><functionalOp displayName="MOST RECENT" type="MOST RECENT" uuid="f96a504e-5a4e-445a-ae45-0f237e8c0b90"><relationalOp displayName="During" type="DURING"><elementRef displayName="Occurrence A of HbA1c Laboratory Test : Laboratory Test, Result" id="40280381-3d61-56a7-013e-622405702579" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-622405702575" type="qdm"/></relationalOp></functionalOp><elementRef displayName="Occurrence A of HbA1c Laboratory Test : Laboratory Test, Result" id="40280381-3d61-56a7-013e-622405702579" type="qdm"><attribute comparisonValue="9" mode="Greater Than" name="result" unit="%"/></elementRef></logicalOp><functionalOp displayName="NOT" type="NOT" uuid="a118c90e-8ac6-4354-8d2d-50e15110ac86"><relationalOp displayName="During" type="DURING"><elementRef displayName="Occurrence A of HbA1c Laboratory Test : Laboratory Test, Result" id="40280381-3d61-56a7-013e-622405702579" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-622405702575" type="qdm"/></relationalOp></functionalOp></logicalOp></logicalOp></clause></group></measureGrouping><elementLookUp><qdm codeSystemName="National Committee for Quality Assurance" datatype="Diagnosis, Active" id="40280381-3d61-56a7-013e-62240570256e" instance="Occurrence A" name="Diabetes" oid="2.16.840.1.113883.3.464.1003.103.12.1001" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-62240570256e" version="1"/><qdm codeSystemName="National Library of Medicine" datatype="Patient Characteristic Sex" id="40280381-3d61-56a7-013e-62240570256f" name="ONC Administrative Sex" oid="2.16.840.1.113762.1.4.1" suppDataElement="true" taxonomy="Administrative Sex" uuid="40280381-3d61-56a7-013e-62240570256f" version="1"/><qdm codeSystemName="CDC NCHS" datatype="Patient Characteristic Race" id="40280381-3d61-56a7-013e-622405702570" name="Race" oid="2.16.840.1.114222.4.11.836" suppDataElement="true" taxonomy="CDC" uuid="40280381-3d61-56a7-013e-622405702570" version="1"/><qdm codeSystemName="CDC NCHS" datatype="Patient Characteristic Ethnicity" id="40280381-3d61-56a7-013e-622405702571" name="Ethnicity" oid="2.16.840.1.114222.4.11.837" suppDataElement="true" taxonomy="CDC" uuid="40280381-3d61-56a7-013e-622405702571" version="1"/><qdm codeSystemName="PHDSC" datatype="Patient Characteristic Payer" id="40280381-3d61-56a7-013e-622405702572" name="Payer" oid="2.16.840.1.114222.4.11.3591" suppDataElement="true" taxonomy="Source of Payment Typology" uuid="40280381-3d61-56a7-013e-622405702572" version="1"/><qdm codeSystemName="National Quality Forum" datatype="Patient Characteristic Birthdate" id="40280381-3d61-56a7-013e-622405702573" name="birth date" oid="2.16.840.1.113883.3.560.100.4" suppDataElement="false" taxonomy="LOINC" uuid="40280381-3d61-56a7-013e-622405702573" version="1"/><qdm codeSystemName="National Quality Forum" datatype="Timing Element" id="40280381-3d61-56a7-013e-622405702575" name="Measurement Period" oid="2.16.840.1.113883.3.67.1.101.1.53" suppDataElement="false" taxonomy="NQF" uuid="40280381-3d61-56a7-013e-622405702575" version="1"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Laboratory Test, Result" id="40280381-3d61-56a7-013e-622405702579" instance="Occurrence A" name="HbA1c Laboratory Test" oid="2.16.840.1.113883.3.464.1003.198.12.1013" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-622405702579" version="1"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Encounter, Performed" id="40280381-3d61-56a7-013e-62240570257c" name="Office Visit" oid="2.16.840.1.113883.3.464.1003.101.12.1001" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-62240570257c" version="1"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Encounter, Performed" id="40280381-3d61-56a7-013e-62240570257d" name="Face-to-Face Interaction" oid="2.16.840.1.113883.3.464.1003.101.12.1048" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-62240570257d" version="1"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Encounter, Performed" id="40280381-3d61-56a7-013e-62240570257e" name="Preventive Care Services - Established Office Visit, 18 and Up" oid="2.16.840.1.113883.3.464.1003.101.12.1025" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-62240570257e" version="1"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Encounter, Performed" id="40280381-3d61-56a7-013e-62240570257f" name="Preventive Care Services-Initial Office Visit, 18 and Up" oid="2.16.840.1.113883.3.464.1003.101.12.1023" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-62240570257f" version="1"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Encounter, Performed" id="40280381-3d61-56a7-013e-622405702580" name="Home Healthcare Services" oid="2.16.840.1.113883.3.464.1003.101.12.1016" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-622405702580" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Encounter, Performed" id="40280381-3d61-56a7-013e-622405712581" name="Annual Wellness Visit" oid="2.16.840.1.113883.3.526.3.1240" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-622405712581" version="1"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Diagnosis, Active" id="40280381-3d61-56a7-013e-622405712582" instance="Occurrence A" name="Gestational Diabetes" oid="2.16.840.1.113883.3.464.1003.103.12.1010" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-622405712582" version="1"/></elementLookUp><strata displayName="Stratification"><clause displayName="Stratum 1" type="stratum" uuid="40280381-3d61-56a7-013e-6224202d25c9"><logicalOp displayName="AND" type="and"/></clause></strata></measure>
